Investment Q&A

Q: What's the reason behind BOS' big 39%+ plunge since the start of 2022? I know it was downgraded by one analyst on 5/02, could be just a case beating a drowning dog while its already hard hit.

What can we expect when BOS reports next week? Thanks.

Q: I own WISH as a portion of my speculative portfolio. Last Wednesday it reported what I thought was another good Q - continued acquisitions, rev up 107%, GP up 119%, Gross Margins of 68% (up from 63%). The stock has continued to tank since the announcement and is down 19% from the day before it announced and down over 50% from its 52 wk high. Am I missing something to this story and the stock is indeed undesirable for some reason, or is the market miss pricing this one? They seem to be doing everything right but I may be missing something and would love your perspective.
Many thanks
Scott

Q: Do you have an update to the information you provided back in Dec. 16, 2020? Thanks.

Q: Could you explain the big drop in share price today. I thought the NR today was not that bad. Thanks

Q: Given the disastrous flood at their Perkoa mine, and now the delay in reporting results, does Trevali have any realistic chance of avoiding their seemingly inevitable swirl down the toilet bowl?

Q: Your thoughts on results?

Q: Q: Hi, Could you please comment on LEV earnings. Thank you

Q: At the time of writing, PRN is up by 10% today. Deeply under water, earnings next week. What to expect? Is it a keeper for the next year or should I sell for tax loss and take my money elsewhere? If a sell, would you wait for earnings? The market is so short term sighted that with COVID PRN might suffer for an extend period of time.

Q: Could you provide an update on the balance sheet of Questor, in particular its balance sheet along with cash and debt positions. Also Insider holdings and trading. Are you concerned that it has not had any press releases in 2022, especially with rising oil and gas prices along with green initiatives. What is your opinion of management. Thanks.

Q: I have held SCL.CA for some time and it has lost much of its value.
Is there any point on keeping it or is it time to move on?

Q: The company easily beat 1st q estimates and raised it's dividend. Granted there may have been big stocking up by customers, but the raise in dividend suggests the outlook it great.

Q: thoughts on quarter thanks

Q: What are your thoughts on earnings and prospects?

Q: Esteemed team, Nickel 28 took a 10%+ hit today but I can find no news that would trigger the selloff. Cobalt and nickel appear to remain in high demand.
Any info or opinions would be appreciated.
With appreciation,
Ed

Q: Re: your comments on ARE below. What's the main reason they have losses ? Is it material costs or fixed price contracts or are they expanding ? Is the negative cash flow being used for good or is it just an overhang ? Thank you.

Q: Hi 5i, big drop today from MITK today. What happened? Would you be inclined to hold?

Thanks!
Kyle

Q: I would appreciate an updated opinion on Blackline. Thanks!

Q: thoughts on quarter

Q: As can be seen from today's NR, we may now be off to the races with OPS. Would appreciate your views.

QUEBEC CITY, April 26, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received Health Canada approval for the SavvyWire™, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR.

Q: Would appreciate your views on this morning's blockbuster announcement. The SP has been very lethargic over the past year but this could finally move the yardsticks.

CINCINNATI, April 26, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce the execution of a national insurance contract with a top five health insurer in the United States1.

Management Commentary

“The execution of this national insurance contract with the largest commercial payer in the United States is a major milestone for Quipt and serves as a further accelerant to our ambitious long term growth plans. The national contract is expected to be meaningful as we continue to expand into new states, broadening our operating footprint over a much wider geography. When we make an acquisition, we will be able to immediately leverage the national contract, which is extremely powerful in terms of capturing as many eligible patients as possible,” said Greg Crawford, Chairman and CEO of Quipt. “Moreover, we feel there's still a lot of opportunity for us to go after more national contracts, which would provide the opportunity to add additional payers, and we will continue to work with other large commercial payers to help them better understand our strong patient centric model and the benefits to patients and payors alike. The new national insurance contract, extremely favorable demographics, and our robust operating platform, put us in an industry leading position to provide high touch at home clinical respiratory services throughout the country.”